Compare SPOK & HELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPOK | HELP |
|---|---|---|
| Founded | 2004 | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 267.8M | 303.9M |
| IPO Year | 2004 | N/A |
| Metric | SPOK | HELP |
|---|---|---|
| Price | $11.83 | $7.82 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $14.00 | N/A |
| AVG Volume (30 Days) | 136.3K | ★ 570.6K |
| Earning Date | 05-28-2026 | 01-01-0001 |
| Dividend Yield | ★ 9.08% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.62 | N/A |
| Revenue | ★ $137,653,000.00 | N/A |
| Revenue This Year | $5.28 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $22.21 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $12.26 | $5.76 |
| 52 Week High | $19.31 | $8.23 |
| Indicator | SPOK | HELP |
|---|---|---|
| Relative Strength Index (RSI) | 27.29 | 62.10 |
| Support Level | N/A | $7.33 |
| Resistance Level | $13.68 | $8.23 |
| Average True Range (ATR) | 0.39 | 0.60 |
| MACD | -0.09 | 0.18 |
| Stochastic Oscillator | 6.00 | 95.65 |
Spok Holdings Inc is a provider of healthcare communications. The company delivers clinical communication and collaboration solutions to help protect the health, well-being, and safety of people in the United States and abroad, on a limited basis, in Europe, Canada, Australia, Asia, and the Middle East. The company develops, sells, and supports enterprise-wide systems principally for healthcare and other organizations needing to automate, centralize, and standardize their approach to clinical and critical communications. The company offers its services and products to three market segments: healthcare, government, and large enterprise, with a greater emphasis on the healthcare market segment. Geographically, the company generates the majority of its revenue from the United States.
Helus Pharma Inc is a clinical-stage pharmaceutical company developing proprietary novel serotonergic agonists (NSAs), which are synthetic molecules designed to activate serotonin pathways associated with neuroplasticity. These compounds are being investigated for potential use in the treatment of depression, anxiety, and other mental health conditions, areas where there is an unmet medical need. It aims to provide treatments designed for mental health disorders. The company is currently developing HLP003, a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment of substantial depressive disorder. It operates in Canada, the United States, the United Kingdom, and Ireland.